Added to YB: 2026-02-20
Pitch date: 2026-02-17
NVO [bullish]
Novo Nordisk A/S
-21.72%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.1T
Pitch Price
DKK 302.64
Price Target
80.00 (-66%)
Dividend
4.94%
EV/EBITDA
7.46
P/E
10.29
EV/Sales
3.74
Sector
Pharmaceuticals
Category
growth
Show full summary:
Top Picks 2026: A Map of Opportunities in Transformational Markets | Novo Nordisk A/S (NVO) — Pillification of the Obesity Market
NVO: Oral GLP-1 pill (Jan 2026 approval) is inflection point: 16.6% weight loss in 64wks, $149-299/mo vs $1k+ injectable, unlocks 100M+ injection-averse Americans. Novo projects oral captures 33%+ of $100B+ GLP-1 market by 2030. Risk: pricing pressure, Lilly competition. PT $80, 5.77% return. Defensive pick.
Read full article (1 min)